|
CYCC
|
Cyclacel Pharmaceuticals, Inc.
|
US
|
NASDAQ
|
|
CYCCP
|
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock
|
US
|
NASDAQ
|
|
CYCN
|
Cyclerion Therapeutics, Inc.
|
US
|
NASDAQ
|
|
CYDY
|
Cytodyn Inc
|
US
|
OTC
|
|
CYP
|
Cynata Therapeutics Ltd
|
AU
|
ASX
|
|
CYTHW
|
Cyclo Therapeutics Inc
|
US
|
US
|
|
CYTK
|
Cytokinetics, Incorporated
|
US
|
NASDAQ
|
|
CYTR
|
Cytrx Corporation
|
US
|
OTC
|
|
CZTA
|
CHECKPOINT THER. DL-0001
|
DE
|
F
|
|
DBV
|
DBV Technologies
|
FR
|
PA
|
|
DBVT
|
DBV Technologies S.A.
|
US
|
NASDAQ
|
|
DCPH
|
Deciphera Pharmaceuticals, Inc.
|
US
|
NASDAQ
|
|
DEST
|
Destiny Pharma Plc
|
UK
|
LSE
|
|
DFFN
|
Diffusion Pharmaceuticals Inc.
|
US
|
NASDAQ
|
|
DGEN
|
Deltagen Inc
|
US
|
US
|
|
DHER34
|
Danaher Corporation
|
BR
|
SA
|
|
DHR
|
Danaher Corporation
|
MX
|
MX
|
|
DMAC
|
DiaMedica Therapeutics Inc.
|
US
|
NASDAQ
|
|
DMTK
|
DermTech, Inc.
|
US
|
NASDAQ
|
|
DMTKW
|
Dermtech Inc WT
|
US
|
OTC
|